Adicet Bio, Inc. Announces Proposed Public Offering of Common Stock
September 21 2020 - 7:00AM
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced that it has
commenced an underwritten public offering of 4,500,000 shares of
its common stock. Adicet also intends to grant the underwriters a
30-day option to purchase up to an additional 675,000 shares of
common stock at the public offering price, less underwriting
discounts and commissions. All of the shares in the proposed
offering are to be sold by Adicet. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
BofA Securities, Jefferies and SVB Leerink are acting as joint
book-running managers for the proposed offering. Wedbush PacGrow is
acting as lead manager for the proposed offering.
The shares are being offered by Adicet pursuant to a shelf
registration statement that was previously filed with, and
subsequently declared effective on February 12, 2019 by, the U.S.
Securities and Exchange Commission (SEC). A preliminary prospectus
supplement relating to and describing the terms of the offering
will be filed with the SEC and will be available on the SEC’s
website at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to these
securities may be obtained, when available, from:
- BofA Securities, NC1-004-03-43; 200 North College Street, 3rd
Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus
Department or by email at dg.prospectus_requests@bofa.com;
- Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by
telephone at (877) 547-4340 or by email at
Prospectus_Department@Jefferies.com; or
- SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by telephone at (800)
808-7525 ext. 6132 or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Adicet
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in
patients.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995, including without limitation, statements
related to the anticipated public offering of shares. These
forward-looking statements include, but are not limited to, those
relating to Adicet expectations regarding the completion, timing
and size of the public offering, and its expectations with respect
to granting the underwriters a 30-day option to purchase additional
shares. Any forward-looking statements in this press release are
based on management’s current expectations and beliefs of future
events, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties related to completion of the proposed
public offering on the anticipated terms, or at all, include, but
are not limited to, market conditions and the satisfaction of
customary closing conditions related to the proposed public
offering. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Adicet’s actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in Adicet’s most recent annual report on Form 10-K filed on March
12, 2020 and our period reports on Form 10-Q and Form 8-K filed
with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Adicet’s other
filings with the SEC, including those contained or
incorporated by reference in the preliminary prospectus supplement
related to the proposed public offering to be filed with the SEC.
All information in this press release is as of the date of the
release, and Adicet undertakes no duty to update this
information unless required by law.
Adicet Bio,
Inc.Investor and Media ContactsAnne
Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Sep 2023 to Sep 2024